Keyword search (4,164 papers available)

"Vuckovic D" Authored Publications:

Title Authors PubMed ID
1 Multi-stimuli-responsive degradable boronic ester-crosslinked e-spun nanofiber wound dressings Casillas-Popova SN; Lokuge ND; Singh P; Cirillo A; Thinphang-Nga A; Skinner CD; Vuckovic D; Findlay BL; Oh JK; 40557709
BIOLOGY
2 Technical recommendations for analyzing oxylipins by liquid chromatography-mass spectrometry Schebb NH; Kampschulte N; Hagn G; Plitzko K; Meckelmann SW; Ghosh S; Joshi R; Kuligowski J; Vuckovic D; Botana MT; Sánchez-Illana Á; Zandkarimi F; Das A; Yang J; Schmidt L; Checa A; Roche HM; Armando AM; Edin ML; Lih FB; Aristizabal-Henao JJ; Miyamoto S; Giuffrida F; Moussaieff A; Domingues R; Rothe M; Hinz C; Das US; Rund KM; Taha AY; Hofstetter RK; Werner M; Werz O; Kahnt AS; Bertrand-Michel J; Le Faouder P; Gurke R; Thomas D; Torta F; Milic I; Dias IHK; Spickett CM; Biagini D; Lomonaco T; Idborg H; Liu J 40392938
CHEMBIOCHEM
3 International interlaboratory study to normalize liquid chromatography-based mycotoxin retention times through implementation of a retention index system Kelman MJ; Renaud JB; McCarron P; Hoogstra S; Chow W; Wang J; Varga E; Patriarca A; Vaya AM; Visintin L; Nguyen T; De Boevre M; De Saeger S; Karanghat V; Vuckovic D; McMullin DR; Dall' Asta C; Ayeni K; Warth B; Huang M; Tittlemier S; Mats L; Cao R; Sulyok M; Xu K; Berthiller F; Kuhn M; Cramer B; Ciasca B; Lattanzio V; De Baere S; Croubels S; DesRochers N; Sura S; Bates J; Wright EJ; Thapa I; Blackwell BA; Zhang K; Wong J; Burns L; Borts DJ; Sumarah MW; 39913989
CHEMBIOCHEM
4 Myelin basic protein mRNA levels affect myelin sheath dimensions, architecture, plasticity, and density of resident glial cells Bagheri H; Friedman H; Hadwen A; Jarweh C; Cooper E; Oprea L; Guerrier C; Khadra A; Collin A; Cohen-Adad J; Young A; Victoriano GM; Swire M; Jarjour A; Bechler ME; Pryce RS; Chaurand P; Cougnaud L; Vuckovic D; Wilion E; Greene O; Nishiyama A; Benmamar-Badel A; Owens T; Grouza V; Tuznik M; Liu H; Rudko DA; Zhang J; Siminovitch KA; Peterson AC; 39023138
CSBN
5 Metabolomics 2023 workshop report: moving toward consensus on best QA/QC practices in LC-MS-based untargeted metabolomics Mosley JD; Dunn WB; Kuligowski J; Lewis MR; Monge ME; Ulmer Holland C; Vuckovic D; Zanetti KA; Schock TB; 38980450
CHEMBIOCHEM
6 Establishing a framework for best practices for quality assurance and quality control in untargeted metabolomics Mosley JD; Schock TB; Beecher CW; Dunn WB; Kuligowski J; Lewis MR; Theodoridis G; Ulmer Holland CZ; Vuckovic D; Wilson ID; Zanetti KA; 38345679
CHEMBIOCHEM
7 Current Practices in LC-MS Untargeted Metabolomics: A Scoping Review on the Use of Pooled Quality Control Samples Broeckling CD; Beger RD; Cheng LL; Cumeras R; Cuthbertson DJ; Dasari S; Davis WC; Dunn WB; Evans AM; Fernández-Ochoa A; Gika H; Goodacre R; Goodman KD; Gouveia GJ; Hsu PC; Kirwan JA; Kodra D; Kuligowski J; Lan RS; Monge ME; Moussa LW; Nair SG; Reisdorph N; Sherrod SD; Ulmer Holland C; Vuckovic D; Yu LR; Zhang B; Theodoridis G; Mosley JD; 38055671
CHEMBIOCHEM
8 Metabolomics 2022 workshop report: state of QA/QC best practices in LC-MS-based untargeted metabolomics, informed through mQACC community engagement initiatives Dunn WB; Kuligowski J; Lewis M; Mosley JD; Schock T; Ulmer Holland C; Zanetti KA; Vuckovic D; 37940740
CHEMBIOCHEM
9 Understanding the impact of radical changes in diet and the gut microbiota on brain function and structure: rationale and design of the EMBRACE study Ben-Porat T; Alberga A; Audet MC; Belleville S; Cohen TR; Garneau PY; Lavoie KL; Marion P; Mellah S; Pescarus R; Rahme E; Santosa S; Studer AS; Vuckovic D; Woods R; Yousefi R; Bacon SL; 37088645
PERFORM
10 Metabolism of anti-inflammatory OXE (oxoeicosanoid) receptor antagonists by nonhuman primates Cossette C; Chourey S; Ye Q; Reddy CN; Wang R; Poulet S; Slobodchikova I; Vuckovic D; Rokach J; Powell WS; 35158054
PERFORM
11 Assessment of solid phase microextraction as a sample preparation tool for untargeted analysis of brain tissue using liquid chromatography-mass spectrometry Reyes-Garcés N; Boyaci E; Gómez-Ríos GA; Olkowicz M; Monnin C; Bojko B; Vuckovic D; Pawliszyn J; 33433374
CHEMBIOCHEM
12 Dissemination and analysis of the quality assurance (QA) and quality control (QC) practices of LC-MS based untargeted metabolomics practitioners Evans AM; O' Donovan C; Playdon M; Beecher C; Beger RD; Bowden JA; Broadhurst D; Clish CB; Dasari S; Dunn WB; Griffin JL; Hartung T; Hsu PC; Huan T; Jans J; Jones CM; Kachman M; Kleensang A; Lewis MR; Monge ME; Mosley JD; Taylor E; Tayyari F; Theodoridis G; Torta F; Ubhi BK; Vuckovic D; 33044703
CONCORDIA
13 Comparison of N-ethyl maleimide and N-(1-phenylethyl) maleimide for derivatization of biological thiols using liquid chromatography-mass spectrometry Russo MST; Napylov A; Paquet A; Vuckovic D; 32016570
PERFORM
14 In Vivo Solid-Phase Microextraction for Sampling of Oxylipins in Brain of Awake, Moving Rats Napylov A; Reyes-Garces N; Gomez-Rios G; Olkowicz M; Lendor S; Monnin C; Bojko B; Hamani C; Pawliszyn J; Vuckovic D; 31697450
CHEMBIOCHEM
15 Novel highly potent OXE receptor antagonists with prolonged plasma lifetimes that are converted to active metabolites in vivo in monkeys. Ye Q, Chourey S, Reddy CN, Wang R, Cossette C, Gravel S, Slobodchikova I, Vuckovic D, Rokach J, Powell WS 31655025
PERFORM
16 Comparison of underivatized silica and zwitterionic sulfobetaine hydrophilic interaction liquid chromatography stationary phases for global metabolomics of human plasma Sonnenberg RA; Naz S; Cougnaud L; Vuckovic D; 31439439
CHEMBIOCHEM
17 Characterization of Phase I and Glucuronide Phase II Metabolites of 17 Mycotoxins Using Liquid Chromatography-High-Resolution Mass Spectrometry Slobodchikova I; Sivakumar R; Rahman MS; Vuckovic D; 31344861
CBAMS
18 Pharmacokinetics and Metabolism of Selective Oxoeicosanoid (OXE) Receptor Antagonists and Their Effects on 5-Oxo-6,8,11,14-eicosatetraenoic Acid (5-Oxo-ETE)-Induced Granulocyte Activation in Monkeys. Cossette C, Chourey S, Ye Q, Nagendra Reddy C, Gore V, Gravel S, Slobodchikova I, Vuckovic D, Rokach J, Powell WS 27766872
PERFORM
19 In vivo α-hydroxylation of a 2-alkylindole antagonist of the OXE receptor for the eosinophil chemoattractant 5-oxo-6,8,11,14-eicosatetraenoic acid in monkeys. Chourey S, Ye Q, Reddy CN, Cossette C, Gravel S, Zeller M, Slobodchikova I, Vuckovic D, Rokach J, Powell WS 28476332
PERFORM
20 Improving negative liquid chromatography/electrospray ionization mass spectrometry lipidomic analysis of human plasma using acetic acid as a mobile-phase additive Monnin C; Ramrup P; Daigle-Young C; Vuckovic D; 29105990
CHEMBIOCHEM
21 Metabolism and pharmacokinetics of a potent N-acylindole antagonist of the OXE receptor for the eosinophil chemoattractant 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) in rats and monkeys. Reddy CN, Alhamza H, Chourey S, Ye Q, Gore V, Cossette C, Gravel S, Slobodchikova I, Vuckovic D, Rokach J, Powell WS 29339225
PERFORM
22 Liquid chromatography - high resolution mass spectrometry method for monitoring of 17 mycotoxins in human plasma for exposure studies Slobodchikova I; Vuckovic D; 29576275
CHEMBIOCHEM
23 Corrigendum to "In vivo α-hydroxylation of a 2-alkylindole antagonist of the OXE receptor for the eosinophil chemoattractant 5-oxo-6,8,11,14-eicosatetraenoic acid in monkeys" [Biochem. Pharmacol. 138 (2017) 107-118]. Chourey S, Ye Q, Reddy CN, Cossette C, Gravel S, Zeller M, Slobodchikova I, Vuckovic D, Rokach J, Powell WS 29754018
PERFORM
24 Novel Highly Potent and Metabolically Resistant Oxoeicosanoid (OXE) Receptor Antagonists That Block the Actions of the Granulocyte Chemoattractant 5-Oxo-6,8,11,14-Eicosatetraenoic Acid (5-oxo-ETE). Chourey S, Ye Q, Reddy CN, Wang R, Cossette C, Gravel S, Slobodchikova I, Vuckovic D, Rokach J, Powell WS 29972644
PERFORM

 

Title:Novel Highly Potent and Metabolically Resistant Oxoeicosanoid (OXE) Receptor Antagonists That Block the Actions of the Granulocyte Chemoattractant 5-Oxo-6,8,11,14-Eicosatetraenoic Acid (5-oxo-ETE).
Authors:Chourey SYe QReddy CNWang RCossette CGravel SSlobodchikova IVuckovic DRokach JPowell WS
Link:https://www.ncbi.nlm.nih.gov/pubmed/29972644?dopt=Abstract
DOI:10.1021/acs.jmedchem.8b00154
Publication:Journal of medicinal chemistry
Keywords:
PMID:29972644 Category:J Med Chem Date Added:2019-05-31
Dept Affiliation: PERFORM
1 Claude Pepper Institute and Department of Chemistry, Florida Institute of Technology , 150 West University Boulevard , Melbourne , Florida 32901-6982 , United States.
2 Meakins-Christie Laboratories, Centre for Translational Biology , McGill University Health Centre , 1001 Decarie Boulevard , Montreal , Quebec H4A 3J1 , Canada.
3 Department of Chemistry and Biochemistry and PERFORM Centre , Concordia University , 7141 Sherbrooke Street West , Montréal , Quebec H4B 1R6 , Canada.

Description:

Novel Highly Potent and Metabolically Resistant Oxoeicosanoid (OXE) Receptor Antagonists That Block the Actions of the Granulocyte Chemoattractant 5-Oxo-6,8,11,14-Eicosatetraenoic Acid (5-oxo-ETE).

J Med Chem. 2018 Jul 26;61(14):5934-5948

Authors: Chourey S, Ye Q, Reddy CN, Wang R, Cossette C, Gravel S, Slobodchikova I, Vuckovic D, Rokach J, Powell WS

Abstract

5-Oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) is a potent lipid mediator that induces tissue eosinophilia via the selective OXE receptor (OXE-R), which is an attractive therapeutic target in eosinophilic diseases. We previously identified indole OXE-R antagonists that block 5-oxo-ETE-induced primate eosinophil activation. Although these compounds possess good oral absorption, their plasma levels decline rapidly due to extensive oxidation of their hexyl side chain. We have now succeeded in dramatically increasing antagonist potency and resistance to metabolism by replacing the hexyl group with phenylpentyl or phenylhexyl side chains. Compared with our previous lead compound S-230, our most potent antagonist, S-C025, has an IC50 (120 pM) over 80 times lower and a substantially longer plasma half-life. A single major metabolite, which retains antagonist activity (IC50, 690 pM) and has a prolonged lifetime in plasma was observed. These new highly potent OXE-R antagonists may provide a novel strategy for the treatment of eosinophilic disorders like asthma.

PMID: 29972644 [PubMed - in process]





BookR developed by Sriram Narayanan
for the Concordia University School of Health
Copyright © 2011-2026
Cookie settings
Concordia University